Scinai Immunotherapeutics Ltd. (SCNI) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SCNI scores 29 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 8 / 20 (ROIC -35%; FCF yield 0%). Cash generation is the weakest structural signal: the company is consuming cash rather than producing it, and the pillar reflects that negative return on invested capital.
• Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). Institutional participation signals are very weak. The holders section contains no data, so the score cannot be reconciled against actual ownership records.
• Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signals score poorly, offering little evidence of insider confidence.
• Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). Beta of 1.0 means the stock moves in line with the market, but the score reflects limited regime-fit advantage.
• Forensic Balance Sheet: 8 / 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The balance sheet shows moderate Altman Z-score territory, weak Piotroski quality (3 of 9), and a Debt/Equity ratio of 0.5.

For a prospective investor evaluating the stock today, these facts point in one direction: the financial and ownership signals are uniformly weak, and the price has already fallen sharply, to $0.52 against a 52-week range of $0.47–$15.5. A low-priced equity with negative margins, negative ROIC, no reported free-cash-flow yield, and minimal institutional or insider support carries high downside risk. Any upside would have to come from a catalyst that changes the cash trajectory, not from valuation support, since the source data offers no earnings-based valuation anchor (P/E and EV/EBITDA are not available in source data).

Per the SEC financials, the company reported operating losses in every period shown, with operating income between $-7.5M and $-9.7M. Gross margin is -30%, operating margin -60%, and net margin -60% per the market data section. Free cash flow was negative in all three periods, and the source reports an FCF yield of 0%. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash fell from $2.0M in FY 2024 to $1.7M in FY 2025 alongside a $-6.1M free-cash outflow. The FY 2024 net income of $4.8M, despite a $-8.6M operating loss, is not explained in the source data and should be treated with caution.

Per the recent news section, the headlines fall into four groups:

• Catalyst (GREEN): A Benzinga report, "Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?", noted a gain in the stock. The article body is not in the source data, so the cause is unverified.
• Market wire (YELLOW), commercial: Stock Titan reported that committed customer orders reached about $7.6 million, up about 300%. This is the strongest operational datapoint in the feed.
• Market wire (YELLOW), financing: TradingView reported a $4M financing deal with shares falling, and Stock Titan indicated the roughly $4 million financing would support manufacturing expansion and customer work. Dilution risk is implied but the terms are not in the source data.
• Risk watch (RED): StocksToTrade reported that Nasdaq compliance risk had faded. The RED light marks the catalyst as a risk-watch item, and the headline itself indicates the company had been facing a listing-compliance issue.
• Market wire (YELLOW), manufacturing: Stock Titan reported a manufacturing deal between a Nasdaq-listed U.S. drugmaker and the company's subsidiary.

Per the Butterfly Supply-Chain Graph, the supply_chain value is NONE, no butterfly links are present, and there are no proprietary signals. The news feed therefore contains the only catalyst information available.

• What is the source of the FY 2024 net income of $4.8M, given an operating loss of $-8.6M? Is it a non-operating or one-time item?
• What are the terms of the roughly $4 million financing, including price, dilution, and whether it is a registered offering or a private placement?
• What does the $7.6 million in committed customer orders represent in revenue timing and contract terms, and how much is expected to convert in the next reporting period?
• What is the company's cash runway given $1.7M in reported cash against a FY 2025 free-cash outflow of $-6.1M?
• What was the nature of the Nasdaq compliance issue and how was it resolved, given the stock's 52-week range of $0.47–$15.5?